Linda Law joins Advicenne as US VP, clinical development and med affairs

Late-stage biopharmaceutical company Advicenne has appointed Linda Law as its new US vice president of clinical development and medical affairs.

Law will take responsibility for the group’s efforts in North America, which are focused on its distal Renal Acidosis (dTRA) candidate and she will report to Advicenne’s chief executive officer Dr Luc-André Granier.

She brings 20 years’ of experience in international pharmaceutical development and medical affairs across a range of therapeutic areas to the group.

Commenting on her appointment, Granier said: “This is a pivotal time for Advicenne and Dr Law’s experience and deep knowledge of US clinical development will be of great value of Advicenne.

“Her appointment also marks the start of the company’s US operations.”

Law’s career has seen her serve in various positions for pharmaceutical companies including Procter & Gamble, Lexicon Pharmaceuticals and she has consulted on evaluation and development projects with Takeda, Confluence and Forest Pharmaceuticals.